IPO registrations (S-1, F-1) · Registrants
NKGen Biotech, Inc.
- SEC CIK
- 1845459 · filings on EDGAR ↗
- Former names
- Graf Acquisition Corp. IV (2021–2023)
- Registration
- Form S-1, first filed 2021-02-23, last 2024-06-27; 2 initial registrations, 6 amendments
- Outcome
- Final prospectus filed 2021-05-24; declared effective 2021-05-20
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- DE
- Business address
- 3001 DAIMLER ST,, Santa Ana, CA 92705
- EDGAR entity type
- operating
- Insiders and CEO pay
- NKGen Biotech, Inc. on the corporate pages
Offering terms
- Final price
- $10.00 per ADS (424B4 filed 2021-05-24, an initial public offering)
- Shares sold
- 15,000,000
- Gross proceeds
- $150,000,000 before underwriting discounts and any over-allotment option
- Listing
- NYSE under the symbol GFOR
- Lead underwriters
- J.P. Morgan (9,750,000 shares); Oppenheimer (5,250,000 shares)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- SEC filer: Graf Acquisition Corp. IV EXACT (CIK (EXACT))
- Person page: Andrew Jin-Chan Cherng Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (TenPercentOwner))
Filings 12
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2021-02-23 | S-1 | S-1 (registration) | Graf Acquisition Corp. IV | 0001104659-21-026802 ↗ |
| 2021-04-12 | S-1/A | S-1/A (amendment) | Graf Acquisition Corp. IV | 0001104659-21-049393 ↗ |
| 2021-05-05 | S-1/A | S-1/A (amendment) | Graf Acquisition Corp. IV | 0001104659-21-061275 ↗ |
| 2021-05-20 | EFFECT | EFFECT (declared effective) | Graf Acquisition Corp. IV | 9999999995-21-002033 ↗ |
| 2021-05-24 | 424B4 | 424B4 (final prospectus) | Graf Acquisition Corp. IV | 0001104659-21-071299 ↗ |
| 2023-08-14 | EFFECT | EFFECT (declared effective) | Graf Acquisition Corp. IV | 9999999995-23-002371 ↗ |
| 2023-10-19 | S-1 | S-1 (registration) | NKGen Biotech, Inc. | 0001104659-23-110175 ↗ |
| 2023-11-29 | S-1/A | S-1/A (amendment) | NKGen Biotech, Inc. | 0001104659-23-122107 ↗ |
| 2023-12-15 | S-1/A | S-1/A (amendment) | NKGen Biotech, Inc. | 0001104659-23-126438 ↗ |
| 2024-05-13 | S-1/A | S-1/A (amendment) | NKGen Biotech, Inc. | 0001213900-24-042376 ↗ |
| 2024-06-27 | S-1/A | S-1/A (amendment) | NKGen Biotech, Inc. | 0001213900-24-056687 ↗ |
| 2024-07-08 | EFFECT | EFFECT (declared effective) | NKGen Biotech, Inc. | 9999999995-24-002089 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2021-05-05 | S-1/A | registration statement | $10.00 | 15,000,000 | $150,000,000 | NYSE GFOR | 2 | primary document; price sentence, shares headline, proceeds table, cover names 2 | document ↗ | |
| 2021-05-24 | 424B4 | final prospectus | $10.00 | 15,000,000 | $150,000,000 | NYSE GFOR | 2 | primary document; price sentence, shares headline, proceeds table, underwriting table 2, cover names 2 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Cruz Anatolio B III | Director | 1 | 2021 | ||
| Garcia Gus | Director,Officer | Co-President | 2 | 2021 | |
| Graf Acquisition Partners IV LLC | Officer,TenPercentOwner; TenPercentOwner | Chief Executive Officer | 8 | 2021–2024 | |
| Graf James A | Officer; Officer,TenPercentOwner | Chief Executive Officer; Chief Financial Officer; Interim CFO | 12 | 2021–2024 | |
| Kuznik Anthony A | Officer | EVP, GC and Secretary | 1 | 2021 | |
| Manischewitz Jeanne L. | Director | 1 | 2021 | ||
| McKee Sabrina | Officer | EVP, Strategy | 1 | 2021 | |
| Ramamurti Anantha | Officer | CFO and Treasurer | 1 | 2021 | |
| RIGAUD EDWIN | Director | 1 | 2021 | ||
| Silberman Lewis | Director,Officer | Co-President | 1 | 2021 | |
| LEBENTHAL ALEXANDRA | Director | 1 | 2021 | ||
| Cross Sterling | Officer | CFO and Treasurer | 1 | 2022 | |
| Gagnon Pierre | Officer | Chief Operating Officer | 2 | 2023–2024 | |
| Kim Yong Man | Officer | CSO and CIO | 2 | 2023–2024 | |
| Klowden Michael | Director | 3 | 2023–2024 | ||
| McNulty Alana B. | Director | 1 | 2023 | ||
| NKMAX Co., Ltd. | TenPercentOwner | 2 | 2023 | ||
| Park Sangwoo | Director,TenPercentOwner,Other | 2 | 2023 | ||
| Scott Kathleen D. | Director | 3 | 2023–2024 | ||
| Song Paul Y. | Director,Officer; Officer | Chief Executive Officer | 8 | 2023–2025 | |
| Gottardis Marco | Director | 2 | 2024 | ||
| CFIC-2015 NV Family Investments, LLC | TenPercentOwner | 2 | 2024–2025 | ||
| Cherng Andrew Jin-Chan | TenPercentOwner | 2 | 2024–2025 | person page Fuzzy | |
| CHERNG PEGGY | TenPercentOwner | 2 | 2024–2025 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Plan sponsor | NKGEN BIOTECH | CA | Form 5500 (employee benefit plans) | name and state |
| IPO registrant | STEC, INC. | CA | IPO registrations (S-1, F-1) | same street address and ZIP code, 3001 DAIMLER ST 92705 (FUZZY: a shared address, not proof of a shared organization) |
| SEC filer | NKGen Biotech, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | NKGEN BIOTECH, INC. | CA | Trademarks (USPTO) | name and state |
| Person page | Andrew Jin-Chan Cherng | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (TenPercentOwner) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Biological Products, (No Diagnostic Substances), CA first:
- SANGAMO THERAPEUTICS, INC CA
- GENITOPE CORP CA
- ABGENIX INC CA
- COLLATERAL THERAPEUTICS INC CA
- Life Technologies Corp CA
- DRUGABUSE SCIENCES INC CA
- STRATAGENE CORP CA
- Cordex Pharma, Inc. CA
- COTHERIX INC CA
- Cardiff Oncology, Inc. CA
In other datasets, the same topic (Health) in CA:
- Nonprofit: 24 HOUR CANCER DANCE-A-THON (Nonprofits (IRS Form 990))
Interests: Biological Products, (No Diagnostic Substances) · Health